REPLIGEN Earnings|Guidance|M&A Tuesday, July 28, 2026 +0.67 Positive

Rigen reports Q2 2026 results, raises guidance

Repligen reported 13% organic Q2 2026 revenue growth and raised its FY26 guidance, while announcing a definitive agreement to acquire BioLife Solutions.

View original filing at SEC.gov →

AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day